Full title: LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
Age: 6 months – 25 years
Phase: 1/2
Locations:
- Cardiff- University Hospital Wales
- London- University College London Hospital
- Newcastle- Royal Victoria Infirmary-Great North Children’s Hospital
- Sutton-Royal Marsden Hospital
Brief summary:
This substudy is part of a larger research study. It will look at how safe and effective the drug zilovertamab vedotin is in paediatric and young adult patients with certain cancers that have come back or not responded to treatment, including some blood cancers, neuroblastoma, and Ewing sarcoma.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
